Register a trial

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT03793231




Registration number
NCT03793231
Ethics application status
Date submitted
15/12/2018
Date registered
4/01/2019

Titles & IDs
Public title
fungalAi for Fungal Surveillance & Antifungal Stewardship
Scientific title
Innovative Use of fungalAi for Antifungal Stewardship in Haematology-oncology Patients
Secondary ID [1] 0 0
012018
Secondary ID [2] 0 0
43127/MonH-2018-152967
Universal Trial Number (UTN)
Trial acronym
fungalAi
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Fungal Infections 0 0
Condition category
Condition code
Infection 0 0 0 0
Other infectious diseases

Intervention/exposure
Study type
Observational
Patient registry
Target follow-up duration
Target follow-up type
Description of intervention(s) / exposure
Other interventions - fungalAi platform technology

Fungal Cases - Patients with confirmed invasive fungal infections according to internationally accepted criteria identified by active manual surveillance. Clinical data will be sent to fungalAi platform technology for disease classification.

Control patients - Patients without invasive fungal infections.Clinical data will be sent to fungalAi platform technology for disease classification.


Other interventions: fungalAi platform technology
Electronic surveillance and radiologic diagnosis of invasive fungal infections using fungalAi and associated methodologies.
Intervention code [1] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Accuracy of electronic surveillance using fungalAi natural language processing compared to active manual methods for detection of fungal pneumonia
Timepoint [1] 0 0
12 months
Secondary outcome [1] 0 0
Accuracy of disease classification of deep learning based image analysis for fungal pneumonia at scan level.
Timepoint [1] 0 0
12 months
Secondary outcome [2] 0 0
Accuracy of feature detection of fungal pneumonia using deep learning based image analysis of chest CT compared to radiologist expertise.
Timepoint [2] 0 0
12 months
Secondary outcome [3] 0 0
Accuracy of disease classification of an expert system integrating microbiology and antifungal drug prescriptions with text and image analysis compared to active manual surveillance.
Timepoint [3] 0 0
12 months

Eligibility
Key inclusion criteria
* Adults and children
* Under the haematology service at participating sites
* Inpatient and ambulatory patients.
Minimum age
No limit
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
No exclusion criteria

Study design
Purpose
Duration
Selection
Timing
Prospective
Statistical methods / analysis

Recruitment
Recruitment status
UNKNOWN
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/01/2019
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
30/12/2020
Actual
Sample size
Target
1000
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 0 0
Alfred Health - Melbourne
Recruitment postcode(s) [1] 0 0
- Melbourne

Funding & Sponsors
Primary sponsor type
Government body
Name
Bayside Health
Address
Country
Other collaborator category [1] 0 0
Other
Name [1] 0 0
Monash University
Address [1] 0 0
Country [1] 0 0
Other collaborator category [2] 0 0
Other
Name [2] 0 0
Monash Health
Address [2] 0 0
Country [2] 0 0
Other collaborator category [3] 0 0
Other
Name [3] 0 0
Eastern Health
Address [3] 0 0
Country [3] 0 0
Other collaborator category [4] 0 0
Other
Name [4] 0 0
Western Sydney Local Health District
Address [4] 0 0
Country [4] 0 0
Other collaborator category [5] 0 0
Other
Name [5] 0 0
SA Health
Address [5] 0 0
Country [5] 0 0
Other collaborator category [6] 0 0
Other
Name [6] 0 0
Fremantle Hospital and Health Service
Address [6] 0 0
Country [6] 0 0
Other collaborator category [7] 0 0
Government body
Name [7] 0 0
Singhealth Foundation
Address [7] 0 0
Country [7] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Michelle Dr Ananda-Rajah
Address 0 0
The Alfred
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
What data in particular will be shared?
De-identified individual participant data will be made available in aggregate form for reports, presentations and publications.

Supporting document/s available: Study protocol, Statistical analysis plan (SAP), Clinical study report (CSR)
When will data be available (start and end dates)?
Data will be made available within 6-12 months after study completion.
Available to whom?
Access to study protocol, SAP, CSR will be made publicly available. Access to IPD including individual labelled data will be reviewed by an external independent review panel to ensure that all ethical issues have been met.
Available for what types of analyses?
How or where can data be obtained?
IPD available at link: http://fungalai.com


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.


Results not provided in https://clinicaltrials.gov/study/NCT03793231